CoChat

Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection

Wong, Grace Lai-Hung, Wong, Vincent Wai-Sun, Hui, Vicki Wing-Ki, Yip, Terry Cheuk-Fung, Tse, Yee-Kit, Liang, Lilian Yan, Lui, Rashid Nok-Shun, Mok, Tony Shu-Kam, Chan, Henry Lik-Yuen, Chan, Stephen Lam · 2021 · American Journal of Gastroenterology
Cited by 51

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Immunotherapy has dramatically improved the survival of patients with advanced or metastatic malignancies. Recent studies suggest that immunotherapy may increase the risk of hepatitis, whereas it may also induce functional cure of chronic hepatitis B virus (HBV) infection. We evaluated the incidence of hepatitis flare, HBV reactivation, hepatitis B surface antigen (HBsAg) seroclearance or seroreversion in patients with current or past HBV infection who had received immunotherapy. METHODS: This was a territory-wide observational cohort study in Hong Kong. We identified patients through electronic medical records based on the prescriptions of immune checkpoint inhibitors from July 1, 2014, to December 31, 2019. Patients who were HBsAg positive or HBsAg negative with results for antibody to hepatitis B surface or core antigen (anti-HBs or anti-HBc) were included. RESULTS: A total of 990 patients (397 HBsAg-positive, 593 HBsAg-negative with 482 anti-HBc and/or anti-HBs positive, and 111 both anti-HBc and anti-HBs negative) were identified. All of HBsAg-positive and 15.9% HBsAg-negative patients were put on oral antiviral treatment. Hepatitis flare (alanine aminotransferase >2 times of the upper limit of normal) occurred in 39.3% HBsAg-positive and 30.4% HBsAg-negative patients. High baseline alanine aminotransferase and combination of immunotherapy increased the risk of hepatitis. HBV reactivation (≥2 log increase in HBV DNA from baseline) occurred in 2 HBsAg-positive patients; HBsAg seroclearance and seroreversion was observed in 1 HBsAg-positive and 1 HBsAg-negative patient, respectively (<1%). DISCUSSION: Hepatitis flare occurs in approximately 40% of HBsAg-positive patients and 30% of HBsAg-negative patients during immunotherapy. HBV reactivation, HBsAg seroclearance, and HBsAg seroreversion are rare. Current or past HBV infection has no impact on the emergence of hepatic flare associated with immunotherapy.

Overview

Integrity signals

Registry

Crossref · 10.14309/ajg.0000000000001142

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 4 references

Research works printed but not linked: 27

  1. 2018, Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study, Lancet Gastroenterol Hepatol, 3, 383, 10.1016/S2468-1253(18)30056-6 · DOI · Paper page
  2. Yip, 2017, Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance, J Hepatol, 67, 902, 10.1016/j.jhep.2017.06.019 · DOI
  3. Yip, 2019, HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues, J Hepatol, 70, 361, 10.1016/j.jhep.2018.10.014 · DOI · Paper page
  4. Yip, 2018, Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients, J Hepatol, 68, 63, 10.1016/j.jhep.2017.09.018 · DOI
  5. 2017, EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection, J Hepatol, 67, 370, 10.1016/j.jhep.2017.03.021 · DOI · Paper page
  6. Sarin, 2016, Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update, Hepatol Int, 10, 1, 10.1007/s12072-015-9675-4 · DOI · Paper page
  7. Yip, 2019, Current knowledge of occult hepatitis B infection and clinical implications, Semin Liver Dis, 39, 249, 10.1055/s-0039-1678728 · DOI
  8. Esteva, 2019, Immunotherapy and targeted therapy combinations in metastatic breast cancer, Lancet Oncol, 20, e175, 10.1016/S1470-2045(19)30026-9 · DOI · Paper page
  9. Gong, 2018, Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations, J Immunother Cancer, 6, 8, 10.1186/s40425-018-0316-z · DOI · Paper page
  10. Wong, 2019, Hepatic adverse events of immune checkpoint inhibitors: A territory-wide cohort study, Hepatology, 70, 1223A
  11. Likhitsup, 2019, Understanding the natural history of hepatitis B virus infection and the new definitions of cure and the endpoints of clinical trials, Clin Liver Dis, 23, 401, 10.1016/j.cld.2019.04.002 · DOI
  12. Wong, 2018, Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B, J Hepatol, 69, 793, 10.1016/j.jhep.2018.05.009 · DOI
  13. Wong, 2020, Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure, J Hepatol, 72, 57, 10.1016/j.jhep.2019.08.023 · DOI
  14. Lai, 2018, Chronic hepatitis B increases liver-related mortality of patients with acute hepatitis E: A territorywide cohort study from 2000 to 2016, Clin Infect Dis, 67, 1278, 10.1093/cid/ciy234 · doi:10.1093/cid/ciy234
  15. Wong, 2017, Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: A propensity score weighted landmark analysis, Aliment Pharmacol Ther, 46, 1001, 10.1111/apt.14341 · DOI
  16. Tang, 2018, Comprehensive analysis of the clinical immuno-oncology landscape, Ann Oncol, 29, 84, 10.1093/annonc/mdx755 · DOI · Paper page
  17. Cheng, 2020, Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma, J Hepatol, 72, 307, 10.1016/j.jhep.2019.09.025 · DOI · Paper page
  18. Mondaca, 2020, Clinical implications of drug-induced liver injury in early-phase oncology clinical trials, Cancer, 126, 4967, 10.1002/cncr.33153 · DOI
  19. McGahey, 2017, Reviewing concomitant medications for participants in oncology clinical trials, Am J Health Syst Pharm, 74, 580, 10.2146/ajhp151052 · DOI
  20. Zhang, 2020, Histologic patterns of liver injury induced by anti-PD-1 therapy, Gastroenterol Rep (Oxf), 8, 50, 10.1093/gastro/goz044 · DOI
  21. Fisicaro, 2010, Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B, Gastroenterology, 138, 682, 10.1053/j.gastro.2009.09.052 · DOI · Paper page
  22. Cheng, 2011, Reactivation of hepatitis B virus after steroid treatment in rheumatic diseases, J Rheumatol, 38, 181, 10.3899/jrheum.100692 · doi:10.3899/jrheum.100692
  23. Tsai, 2006, Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents, Dig Dis Sci, 51, 1627, 10.1007/s10620-006-9074-8 · doi:10.1007/s10620-006-9074-8
  24. Onozawa, 2005, Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection, Transplantation, 79, 616, 10.1097/01.TP.0000151661.52601.FB · DOI · Paper page
  25. Loomba, 2017, Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: Current concepts, management strategies, and future directions, Gastroenterology, 152, 1297, 10.1053/j.gastro.2017.02.009 · DOI · Paper page
  26. Wong, 2019, Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B, Liver Int, 39, 271, 10.1111/liv.13953 · DOI
  27. Yip, 2020, Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China, Gastroenterology, 158, 215, 10.1053/j.gastro.2019.09.025 · DOI · Paper page

Cited by

See all 51

Metadata

Authors
Wong, G. L.-H., Wong, V. W.-S., Hui, V. W.-K., Yip, T. C.-F., Tse, Y.-K., Liang, L. Y., Lui, R. N.-S., Mok, T. S.-K., Chan, H. L.-Y., & Chan, S. L.
Affiliations
  • Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong SAR, China;
  • State Key Laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Venue
American Journal of Gastroenterology
Published
2021-01-28
Volume
116
Issue
6
Pages
1274-1283
ISSN
  • 0002-9270
  • 1572-0241
Cited by
51
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. https://app.cochat.ai/papers/10.14309/ajg.0000000000001142
The paper
Wong, G. L.-H., Wong, V. W.-S., Hui, V. W.-K., Yip, T. C.-F., Tse, Y.-K., Liang, L. Y., Lui, R. N.-S., Mok, T. S.-K., Chan, H. L.-Y., & Chan, S. L. (2021). Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000001142

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.